$2.95 -$0.04 (-1.3%)

04:00 PM EST on 12/06/19

PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Current Price $2.95 Mkt Cap $336.8M
Open $3.00 P/E Ratio 488.90
Prev. Close $2.99 Div. (Yield) $0.00 (0.0%)
Daily Range $2.95 - $3.03 Volume 536,162
52-Wk Range $2.06 - $3.89 Avg. Daily Vol. 1,133,938

Caps

How do you think NASDAQ:PDLI will perform against the market?

Add Stock to CAPS Watchlist

All Players

818 Outperform
42 Underperform
 

All-Star Players

127 Outperform
10 Underperform
 

Wall Street

7 Outperform
1 Underperform
 

Top NASDAQ:PDLI Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

LarkinSoft (99.86)
Submitted October 29, 2015

Screened result of <=15 P/E, yields between 8-20%. Then, Current Yield divided by square root of price, adjusted for P/E, LT Debt ratio, and price % above 12-month low. Pick is within top 15 of resulting list. Premise: stock may or may not grow, but… More

mooandjeff (99.86)
Submitted September 02, 2016

In the 2nd Quarter 2016 their year over year net quarterly income fell from 78 million to 4 million, due to the loss of all income from the expired royalty agreement on all of their Queen et al patents in their contract with Genetech. Out of that 4… More

NASDAQ:PDLI VS S&P 500 (SPY)

Fools bullish on NASDAQ:PDLI are also bullish on:

Fools bearish on NASDAQ:PDLI are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about PDLI.

Recs

0
Member Avatar Bigsef77 (69.72) Submitted: 1/14/2019 9:36:47 AM : Outperform Start Price: $3.24 NASDAQ:PDLI Score: -31.94

Hedge Funds Are Buying PDL BioPharma Inc. (PDLI)
Nina Todic
,Insider Monkey‚ÄĘDecember 23, 2018

Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in October due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 30 S&P 500 stocks among hedge funds at the end of September 2018 returned an average of 6.7% through November 15th whereas the S&P 500 Index ETF gained only 2.6% during the same period. Because their consensus picks have done well, we pay attention to what elite funds think before doing extensive research on a stock. In this article, we take a closer look at PDL BioPharma Inc. (NASDAQ:PDLI) from the perspective of those elite funds.

Recs

0
Member Avatar Eskilf (38.76) Submitted: 7/31/2018 2:40:17 PM : Outperform Start Price: $2.50 NASDAQ:PDLI Score: +6.21

MM

Recs

0
Member Avatar MonkeyPick (77.75) Submitted: 8/17/2017 11:19:36 AM : Outperform Start Price: $2.81 NASDAQ:PDLI Score: -23.13

Zacks momentum pick 2-3 .50

Leaderboard

Find the members with the highest scoring picks in PDLI.

Score Leader

Vinyl88

Vinyl88 (98.15) Score: +281.48

The Score Leader is the player with the highest score across all their picks in PDLI.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Vinyl88 98.15 3/24/2009 Underperform 1Y $2.74 +7.81% +289.29% +281.48 0 Comment
heybluewhy 86.79 4/28/2009 Underperform 3Y $3.11 -5.25% +270.30% +275.55 1 Comment
ReadEmAnWeep 44.06 7/30/2009 Underperform 5Y $3.84 -23.13% +220.08% +243.21 0 Comment
hwyman64 < 20 10/15/2008 Underperform 1Y $2.45 +20.65% +238.64% +217.99 0 Comment
JulesWinnfield 99.45 12/14/2009 Underperform 5Y $3.98 -25.79% +181.44% +207.24 0 Comment
striper56 72.24 12/4/2009 Underperform NS $3.63 -18.67% +183.88% +202.54 0 Comment
jroren 98.99 6/21/2010 Underperform 3M $3.31 -10.95% +178.33% +189.28 0 Comment
nitraMcoD < 20 8/25/2006 Underperform 5Y $3.79 -22.14% +159.04% +181.18 1 Comment
predfern 63.69 9/18/2006 Underperform 3Y $3.93 -25.01% +153.61% +178.62 1 Comment
boonet105 82.54 9/20/2006 Underperform 3M $3.84 -23.14% +152.70% +175.84 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for PDLI.